{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"199"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"}],"units":"Participants"}],"description":"Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.","groups":[{"description":"A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia. This is a multicenter(16 sites in the USA), open-label, monotherapy, long-term extension study designed to evaluate the long-term (\\> 6 months) safety and tolerability of a fixed daily dosing regimen of ibrutinib. Ibrutinib was supplied as 140 mg or 40 mg capsules for oral administration. Subjects were to receive daily administration of a fixed dose of ibrutinib at the same dose level as in the parent study (up to 840 mg).","id":"OG000","title":"A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"30 days after last dose of study drug, continue up to 6 months","title":"Number of Subjects With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}